Digital Content 
NEWS #PharmaBuzz
30 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/30/3178040/7767/en/MediciNova-Compounds-Demonstrate-Novel-Therapeutic-Approach-for-Atherosclerosis-in-Peer-Reviewed-Publication.html
28 May 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/05/28/2888826/7767/en/MediciNova-Announces-Two-Poster-Presentations-at-the-92nd-EAS-Congress-2024-the-Annual-Meeting-of-the-European-Atherosclerosis-Society-Regarding-the-Use-of-MN-001-Tipelukast-for-Ca.html
06 Dec 2022
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2022/12/06/2568859/0/en/X4-Pharmaceuticals-Announces-Proposed-Public-Offering.html
13 Sep 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/09/13/2515539/7767/en/MediciNova-Receives-a-Notice-of-Allowance-for-a-New-Patent-Covering-MN-001-and-MN-002-for-the-Treatment-of-Hypertriglyceridemia-Hypercholesterolemia-and-Hyperlipoproteinemia-in-Can.html
09 Aug 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/08/09/2495425/7767/en/MediciNova-Announces-MN-001-tipelukast-Abstract-regarding-Improvement-of-Serum-Lipid-Panel-in-Type-2-Diabetes-and-NAFLD-Patients-Accepted-for-Presentation-at-the-IDF-2022-Congress-.html
26 Jul 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/07/26/2485685/7767/en/MediciNova-Announces-Initiation-of-a-Phase-2-Trial-of-MN-001-tipelukast-in-NAFLD-with-Type-2-Diabetes-Mellitus-and-Hypertriglyceridemia.html
Share 